Back to search

Peptide record

TPDB91237

Magainin 2 Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91237
Magainin 2
Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides Functional / health-promoting peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 i2APP AI4AVP DRAVP 2.0 CPPsite3.0 APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 23-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIGKFLHSAKKFGKAFVGEIMNS-NH2
Physicochemical Analysis
C114H180N30O29S1
RDCQPTWY
GK
2466.93
10.55
5
1
10
+3
2.59
0.083
72.17
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
3
Residue Composition
number
2
A
0
R
1
N
0
D
0
C
1
E
0
Q
4
G
1
H
2
I
1
L
4
K
1
M
3
F
0
P
2
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 4 H: 1 I: 2 L: 1 K: 4 M: 1 F: 3 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
23
C114H180N30O29S1
2466.93
10.55
+3
2.59
0.083
Amidation
L
Linear
Linear
Free
Antibacterial Antimicrobial
African clawed frog Xenopus laevis skin Xenopus laevis
N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O
Evidence Records 21 records
Evidence 1 Activity

Activity

IC50
IC50=110 µM
Anticancer
110 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1993

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

IC50
IC50=32.3 µM
Anticancer
32.3 µM

Target

Bladder Cancer
RT4(G1)
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 3 Activity

Activity

IC50
IC50=54.1 µM
Anticancer
54.1 µM

Target

Bladder Cancer
647V(G2)
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 4 Activity

Activity

IC50
IC50=28.6 µM
Anticancer
28.6 µM

Target

Bladder Cancer
486P(G4)
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 5 Activity

Activity

IC50
IC50=484 µM
Anticancer
484 µM

Target

Bladder Cancer
RT4(G1)
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 6 Activity

Activity

IC50
IC50=52.4 µM
Anticancer
52.4 µM

Target

Bladder Cancer
647V(G2)
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 7 Activity

Activity

IC50
IC50=57.8 µM
Anticancer
57.8 µM

Target

Bladder Cancer
486P(G4)
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 8 Activity

Activity

IC50
IC50=135.3 µM
Anticancer
135.3 µM

Target

Bladder Cancer
RT4(G1)
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 9 Activity

Activity

IC50
IC50=31 µM
Anticancer
31 µM

Target

Bladder Cancer
647V(G2)
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 10 Activity

Activity

IC50
IC50=59.4 µM
Anticancer
59.4 µM

Target

Bladder Cancer
486P(G4)
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 11 Activity

Activity

IC50
IC50 >150 µg/ml
Anticancer
150 µg/mL

Target

Lymphoma Cancer
U-937
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 12 Activity

Activity

IC50
IC50 >150 µg/ml
Anticancer
150 µg/mL

Target

Leukemia Cancer
8402
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 13 Activity

Activity

IC50
IC50 >150 µg/ml
Anticancer
150 µg/mL

Target

Hematopoietic Cancer
SSKT-1
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 14 Activity

Activity

IC50
IC50 >150 µg/ml
Anticancer
150 µg/mL

Target

Colon Cancer
Daudi
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 15 Activity

Activity

IC50
IC50 >150 µg/ml
Anticancer
150 µg/mL

Target

Leukemia Cancer
MLA
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 16 Activity

Activity

IC50
IC50 >150 µg/ml
Anticancer
150 µg/mL

Target

Lymphoma Cancer
Raji
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 17 Activity

Activity

IC50
IC50 >150 µg/ml
Anticancer
150 µg/mL

Target

Leukemia Cancer
K-562
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 18 Activity

Activity

IC50
IC50 >200 µg/ml
Anticancer
200 µg/mL

Target

Ewing sarcoma
CHP-100
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 19 Activity

Activity

IC50
IC50 >200 µg/ml
Anticancer
200 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 20 Activity

Activity

IC50
IC50 >200 µg/ml
Anticancer
200 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

Trypan blue assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 21 Activity

Activity

Cell-penetrating Peptides

Target

HeLa And Huh-7-Luc Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Protein derived
Cy5-plasmid DNA , mRNA , siRNA
Cytosol
In vitro
CCCCCSCCCC
Additional Detail Fields 1 fields
CCCCCSCCCC